| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acting on minimal residual disease in ALL
|
Rytting, Michael
|
|
2014
|
15 |
8 |
p. 777-778
2 p.
|
artikel
|
| 2 |
Addressing overdiagnosis and overtreatment in cancer
|
Coldiron, Brett M
|
|
2014
|
15 |
8 |
p. e307-
1 p.
|
artikel
|
| 3 |
Addressing overdiagnosis and overtreatment in cancer
|
Foucar, Elliott
|
|
2014
|
15 |
8 |
p. e306-e307
nvt p.
|
artikel
|
| 4 |
Adjuvant treatment for gastric cancer: too much is not enough
|
Ilson, David H
|
|
2014
|
15 |
8 |
p. 788-789
2 p.
|
artikel
|
| 5 |
A new combination therapy for premenopausal breast cancer
|
Yaqub, Farhat
|
|
2014
|
15 |
8 |
p. e311-
1 p.
|
artikel
|
| 6 |
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
|
Monk, Bradley J
|
|
2014
|
15 |
8 |
p. 799-808
10 p.
|
artikel
|
| 7 |
2014 ASCO Annual Meeting
|
Sklan, Alex
|
|
2014
|
15 |
8 |
p. 793-794
2 p.
|
artikel
|
| 8 |
ASPECCT: panitumumab versus cetuximab for colorectal cancer
|
Hawkes, Eliza A
|
|
2014
|
15 |
8 |
p. e302-e303
nvt p.
|
artikel
|
| 9 |
ASPECCT: panitumumab versus cetuximab for colorectal cancer
|
Sunakawa, Yu
|
|
2014
|
15 |
8 |
p. e301-e302
nvt p.
|
artikel
|
| 10 |
ASPECCT: panitumumab versus cetuximab for colorectal cancer – Authors' reply
|
Price, Timothy J
|
|
2014
|
15 |
8 |
p. e303-
1 p.
|
artikel
|
| 11 |
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial
|
Vora, Ajay
|
|
2014
|
15 |
8 |
p. 809-818
10 p.
|
artikel
|
| 12 |
Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials
|
Fern, Lorna A
|
|
2014
|
15 |
8 |
p. e341-e350
nvt p.
|
artikel
|
| 13 |
Axitinib: VEGF inhibition in advanced thyroid cancer
|
Bagcchi, Sanjeet
|
|
2014
|
15 |
8 |
p. e310-
1 p.
|
artikel
|
| 14 |
BINGO: targeted therapy for advanced biliary-tract cancer
|
Valle, Juan W
|
|
2014
|
15 |
8 |
p. 778-780
3 p.
|
artikel
|
| 15 |
BOLERO-3 results: pharmacological activity or pharmacokinetic effect?
|
Buti, Sebastiano
|
|
2014
|
15 |
8 |
p. e304-
1 p.
|
artikel
|
| 16 |
BOLERO-3 results: pharmacological activity or pharmacokinetic effect? – Authors' reply
|
André, Fabrice
|
|
2014
|
15 |
8 |
p. e304-e305
nvt p.
|
artikel
|
| 17 |
Cancer Baby: cancer meets Kawaii culture
|
Kuan, Cindy
|
|
2014
|
15 |
8 |
p. 796-797
2 p.
|
artikel
|
| 18 |
Cancer care and research in India: what does it mean to Nepal?
|
Gyawali, Bishal
|
|
2014
|
15 |
8 |
p. e299-e300
nvt p.
|
artikel
|
| 19 |
Cancer care in Sikkim, India
|
Bhatia, Abhijeet
|
|
2014
|
15 |
8 |
p. e301-
1 p.
|
artikel
|
| 20 |
Cancer patients missing out on treatment for heart problems
|
Tanday, Sanjay
|
|
2014
|
15 |
8 |
p. e311-
1 p.
|
artikel
|
| 21 |
Cancer screening education in Chinese medical schools
|
Deng, Lei
|
|
2014
|
15 |
8 |
p. e300-e301
nvt p.
|
artikel
|
| 22 |
Cetuximab for resectable colorectal liver metastasis: New EPOC trial
|
Hasegawa, Kiyoshi
|
|
2014
|
15 |
8 |
p. e305-e306
nvt p.
|
artikel
|
| 23 |
Cetuximab for resectable colorectal liver metastasis: New EPOC trial – Author's reply
|
Primrose, John Neil
|
|
2014
|
15 |
8 |
p. e306-
1 p.
|
artikel
|
| 24 |
Chemoimmunotherapy: still waiting for the magic to happen
|
Nowak, Anna K
|
|
2014
|
15 |
8 |
p. 780-781
2 p.
|
artikel
|
| 25 |
Correction to Lancet Oncol 2013; 14: 199–209
|
|
|
2014
|
15 |
8 |
p. e308-
1 p.
|
artikel
|
| 26 |
Correction to Lancet Oncol 2014; 15: e241
|
|
|
2014
|
15 |
8 |
p. e308-
1 p.
|
artikel
|
| 27 |
Deceptive information and the financial burden for Chinese cancer patients
|
Li, Xing
|
|
2014
|
15 |
8 |
p. e299-
1 p.
|
artikel
|
| 28 |
Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
|
van Leeuwen, Roelof W F
|
|
2014
|
15 |
8 |
p. e315-e326
nvt p.
|
artikel
|
| 29 |
E-cigarette market expands online
|
Bagcchi, Sanjeet
|
|
2014
|
15 |
8 |
p. e313-
1 p.
|
artikel
|
| 30 |
Effect of partial pleurectomy on survival in mesothelioma
|
Yaqub, Farhat
|
|
2014
|
15 |
8 |
p. e314-
1 p.
|
artikel
|
| 31 |
Enzalutamide in castration-resistant prostate cancer
|
Burki, Talha Khan
|
|
2014
|
15 |
8 |
p. e312-
1 p.
|
artikel
|
| 32 |
Federal court judge blocks 340B orphan drug exclusion rule
|
Benmaamar, Ramla
|
|
2014
|
15 |
8 |
p. e313-
1 p.
|
artikel
|
| 33 |
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation
|
Groll, Andreas H
|
|
2014
|
15 |
8 |
p. e327-e340
nvt p.
|
artikel
|
| 34 |
Gefitinib for oesophageal cancer: a cog in need of a wheel?
|
Ford, Hugo E R
|
|
2014
|
15 |
8 |
p. 790-791
2 p.
|
artikel
|
| 35 |
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
|
Dutton, Susan J
|
|
2014
|
15 |
8 |
p. 894-904
11 p.
|
artikel
|
| 36 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|
Middleton, Gary
|
|
2014
|
15 |
8 |
p. 829-840
12 p.
|
artikel
|
| 37 |
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
|
Malka, David
|
|
2014
|
15 |
8 |
p. 819-828
10 p.
|
artikel
|
| 38 |
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial
|
Cook, Gordon
|
|
2014
|
15 |
8 |
p. 874-885
12 p.
|
artikel
|
| 39 |
How safe is a standard-risk child with ALL?
|
Winther, Jeanette Falck
|
|
2014
|
15 |
8 |
p. 782-783
2 p.
|
artikel
|
| 40 |
Ibrutinib monotherapy in chronic lymphoid leukaemia
|
Bagcchi, Sanjeet
|
|
2014
|
15 |
8 |
p. e312-
1 p.
|
artikel
|
| 41 |
Living Funeral
|
van Dorn, Aaron
|
|
2014
|
15 |
8 |
p. 797-798
2 p.
|
artikel
|
| 42 |
Made-to-measure medicine: BRCA and gynaecological cancer
|
Foulkes, William D
|
|
2014
|
15 |
8 |
p. 783-785
3 p.
|
artikel
|
| 43 |
New European clinical trials regulation is published
|
Mayor, Susan
|
|
2014
|
15 |
8 |
p. 792-
1 p.
|
artikel
|
| 44 |
Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review
|
Ahmed, Muneer
|
|
2014
|
15 |
8 |
p. e351-e362
nvt p.
|
artikel
|
| 45 |
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
|
Ledermann, Jonathan
|
|
2014
|
15 |
8 |
p. 852-861
10 p.
|
artikel
|
| 46 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial
|
Taieb, Julien
|
|
2014
|
15 |
8 |
p. 862-873
12 p.
|
artikel
|
| 47 |
Patients with polycystic kidney disease at lower risk of cancer
|
Tanday, Sanjay
|
|
2014
|
15 |
8 |
p. e310-
1 p.
|
artikel
|
| 48 |
Proton therapy for prostate cancer: time for evidence
|
The Lancet Oncology,
|
|
2014
|
15 |
8 |
p. 775-
1 p.
|
artikel
|
| 49 |
Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort
|
Essig, Stefan
|
|
2014
|
15 |
8 |
p. 841-851
11 p.
|
artikel
|
| 50 |
Second transplant as a standard for multiple myeloma
|
McCarthy, Philip L
|
|
2014
|
15 |
8 |
p. 786-788
3 p.
|
artikel
|
| 51 |
Selling hope: advertising and patient expectation
|
Burki, Talha Khan
|
|
2014
|
15 |
8 |
p. 798-
1 p.
|
artikel
|
| 52 |
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial
|
Tsuburaya, Akira
|
|
2014
|
15 |
8 |
p. 886-893
8 p.
|
artikel
|
| 53 |
Siltuximab in transplant-ineligible patients with myeloma
|
Bagcchi, Sanjeet
|
|
2014
|
15 |
8 |
p. e309-
1 p.
|
artikel
|
| 54 |
2014 SNMMI Annual Meeting
|
Smith, Lan-Lan
|
|
2014
|
15 |
8 |
p. 795-
1 p.
|
artikel
|
| 55 |
Societal and political will for cancer prevention in Russia
|
Jargin, Sergei V
|
|
2014
|
15 |
8 |
p. e298-
1 p.
|
artikel
|
| 56 |
Study estimates economic returns from UK cancer research
|
Fricker, Janet
|
|
2014
|
15 |
8 |
p. e314-
1 p.
|
artikel
|
| 57 |
Targeting genetic drivers of lung cancer improves survival
|
Tanday, Sanjay
|
|
2014
|
15 |
8 |
p. e309-
1 p.
|
artikel
|
| 58 |
The wide gulf between stage III and stage IV colon cancer
|
Ting, David T
|
|
2014
|
15 |
8 |
p. 785-786
2 p.
|
artikel
|
| 59 |
Trebananib: an alternative anti-angiogenic strategy
|
Gourley, Charlie
|
|
2014
|
15 |
8 |
p. 776-777
2 p.
|
artikel
|
Tijdschrift beschrijving